Nearly 80% of the approved human therapeutic antibodies are produced by Chinese
Hamster Ovary (CHO) cells. To achieve better cell growth and high-yield recombinant …

In recent years, coherent with growing biologics portfolios also the number of complex and
thus difficult‐to‐express (DTE) therapeutic proteins has increased considerably. DTE …

Chinese hamster ovary (CHO) cells have been routinely used as a factory for recombinant
proteins for several years, and their improvements have been the focus of consideration …

The COVID-19 pandemic has brought global attention towards the readiness of
biotechnology platforms for rapid development of immunogens to be used as vaccine …

Abstract Chinese Hamster Ovary (CHO) cells are the most frequently used
biopharmaceutical production hosts, although industry is presently suffering from their …

The demand for industrial genetically modified host cells were increased with the growth of
the biopharmaceutical market. Numerous studies on improving host cell productivity have …

Especially for the production of artificial, difficult to express molecules a further development
of the CHO production cell line is required to keep pace with the continuously increasing …

The biopharmaceutical industry strives for improvement of their production processes. In
recent years, miRNAs have been shown to positively impact the production capacity of …

The role of non‐coding RNAs in determining growth, productivity, and recombinant product
quality attributes in Chinese hamster ovary (CHO) cells has received much attention in …

In recent years, the number of complex but clinically effective biologicals such as multi‐
specific antibody formats and fusion proteins has increased dramatically. However …